Literature DB >> 20667570

Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.

Anne Schaap-Nutt1, Christopher D'Angelo, Emerito Amaro-Carambot, Sheila M Nolan, Stephanie Davis, Shenelle-Marie Wise, Caraline Higgins, Konrad Bradley, Olivia Kim, Reina Mayor, Mario H Skiadopoulos, Peter L Collins, Brian R Murphy, Alexander C Schmidt.   

Abstract

The HPIV2 V protein inhibits type I interferon (IFN) induction and signaling. To manipulate the V protein, whose coding sequence overlaps that of the polymerase-associated phosphoprotein (P), without altering the P protein, we generated an HPIV2 virus in which P and V are expressed from separate genes (rHPIV2-P+V). rHPIV2-P+V replicated like HPIV2-WT in vitro and in non-human primates. HPIV2-P+V was modified by introducing two separate mutations into the V protein to create rHPIV2-L101E/L102E and rHPIV2-Delta122-127. In contrast to HPIV2-WT, both mutant viruses were unable to degrade STAT2, leaving virus-infected cells susceptible to IFN. Neither mutant, nor HPIV2-WT, induced significant amounts of IFN-beta in infected cells. Surprisingly, neither rHPIV2-L101E/L102E nor rHPIV2-Delta122-127 was attenuated in two species of non-human primates. This indicates that loss of HPIV2's ability to inhibit IFN signaling is insufficient to attenuate virus replication in vivo as long as IFN induction is still inhibited. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20667570      PMCID: PMC2932766          DOI: 10.1016/j.virol.2010.07.011

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  80 in total

1.  Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production.

Authors:  J M Emeny; M J Morgan
Journal:  J Gen Virol       Date:  1979-04       Impact factor: 3.891

2.  Identification of amino acids essential for the human parainfluenza type 2 virus V protein to lower the intracellular levels of the STAT2.

Authors:  Yuji Kozuka; Yasufumi Yamashita; Mitsuo Kawano; Masato Tsurudome; Morihiro Ito; Machiko Nishio; Hiroshi Komada; Yasuhiko Ito
Journal:  Virology       Date:  2003-12-20       Impact factor: 3.616

3.  Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

Authors:  Josephine M McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

4.  Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

Authors:  Robert B Belshe; Frances K Newman; Theodore F Tsai; Ruth A Karron; Keith Reisinger; Don Roberton; Helen Marshall; Richard Schwartz; James King; Frederick W Henderson; William Rodriguez; Joseph M Severs; Peter F Wright; Harry Keyserling; Geoffrey A Weinberg; Kenneth Bromberg; Richard Loh; Peter Sly; Peter McIntyre; John B Ziegler; Jill Hackell; Anne Deatly; Alice Georgiu; Maribel Paschalis; Shin-Lu Wu; Joanne M Tatem; Brian Murphy; Edwin Anderson
Journal:  J Infect Dis       Date:  2004-01-20       Impact factor: 5.226

5.  Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis.

Authors:  J D Mosca; P M Pitha
Journal:  Mol Cell Biol       Date:  1986-06       Impact factor: 4.272

Review 6.  Current approaches to the development of vaccines effective against parainfluenza viruses.

Authors:  B R Murphy
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

7.  Extensive antigenic diversity among human parainfluenza type 2 virus isolates and immunological relationships among paramyxoviruses revealed by monoclonal antibodies.

Authors:  M Tsurudome; M Nishio; H Komada; H Bando; Y Ito
Journal:  Virology       Date:  1989-07       Impact factor: 3.616

8.  Specific inhibition of type I interferon signal transduction by respiratory syncytial virus.

Authors:  Murali Ramaswamy; Lei Shi; Martha M Monick; Gary W Hunninghake; Dwight C Look
Journal:  Am J Respir Cell Mol Biol       Date:  2004-01-12       Impact factor: 6.914

9.  Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Authors:  Jason T Newman; Jeffrey M Riggs; Sonja R Surman; Josephine M McAuliffe; Teresa A Mulaikal; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected].

Authors:  Kirsten M Spann; Kim-C Tran; Bo Chi; Ronald L Rabin; Peter L Collins
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  6 in total

1.  Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Authors:  Anne Schaap-Nutt; Caraline Higgins; Emerito Amaro-Carambot; Sheila M Nolan; Christopher D'Angelo; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 2.  Paramyxovirus evasion of innate immunity: Diverse strategies for common targets.

Authors:  Michelle D Audsley; Gregory W Moseley
Journal:  World J Virol       Date:  2013-05-12

Review 3.  Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.

Authors:  Henrick Schomacker; Anne Schaap-Nutt; Peter L Collins; Alexander C Schmidt
Journal:  Curr Opin Virol       Date:  2012-03-03       Impact factor: 7.090

4.  Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium.

Authors:  Anne Schaap-Nutt; Rachael Liesman; Emmalene J Bartlett; Margaret A Scull; Peter L Collins; Raymond J Pickles; Alexander C Schmidt
Journal:  Virology       Date:  2012-09-07       Impact factor: 3.616

5.  The V protein of Tioman virus is incapable of blocking type I interferon signaling in human cells.

Authors:  Grégory Caignard; Marianne Lucas-Hourani; Kevin P Dhondt; Jean-Louis Labernardière; Thierry Petit; Yves Jacob; Branka Horvat; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

6.  The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome.

Authors:  Henrick Schomacker; Rebecca M Hebner; Jim Boonyaratanakornkit; Sonja Surman; Emerito Amaro-Carambot; Peter L Collins; Alexander C Schmidt
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.